hxrts

git-ssb was one of the inspirations for Radicle, we're big fans of the project and we've spoken to cel, the author of that project a few times. one of the most meaningful distinctions is visibility in the network, git-ssb repos are distributed through the Scuttlebutt social graph, while Radicle projects are seesed to the whole network. We've written a little on this in the FAQ, 4th question: http://radicle.xyz/docs/#faq

Digital artist Jeremiah Johnson using a beta release: https://www.instagram.com/p/_TFWRWK6Xh/

This needs to be front and center. Data protections / PHI are the #1 issue for academic groups in the field. – bioinformatician

Seems this could play quite well with IPFS.

Bruno Latour's response to this text can be found here: http://entitleblog.org/2015/06/27/fifty-shades-of-green-brun...

Requisite Pitagora Switch Rube Goldberg compilation video: https://www.youtube.com/watch?v=NzAQ-jYfEqA

I quite enjoyed the parallel made between physics and economics and the subsequent case against such a comparison. There is a strong argument against a traditional notion of efficient markets here.

What do you think are some of the important milestones in between? We've gotten similar criticism before but it would be helpful to fill in those gaps. The piece was edited for length, hence the 'brief,' and we knew there would be quite a bit missing.

Hi HN,

Editor-in-chief of avant.org here (& editor of said piece). Very surprised/pleased to see this link pop up while browsing the front page.

The author had a good deal of additional material that we cut down to form this brief survey, and I'm sure all of you have some great resources as well. If so, post them here. I'd love to share with our readers!

We are a (soon to be) non-profit that publishes critical, cross-disciplinary essays, frequently about science and technology. If that's your thing, consider finding us on twitter: @avantdotorg

Also, a few other pieces that have cropped up on HN before if you're so inclined:

• http://avant.org/media/stealth-infrastructure

• http://avant.org/media/75k-futures

Looking forward to your comments! Always a thrill to have one of our pieces circulate here.

I have a hard time believing doctors will be replaced in large numbers. The nature of their jobs may shift away from hypothesis generation but ultimately a human will be making the final diagnosis, choosing from several options that have been vetted algorithmically. Legally & practically a human needs to arbitrate that process, people would feel uncomfortable otherwise.

Not familiar with the lab personally but this is probably close to the state of the art right now. http://pubs.acs.org/doi/abs/10.1021/nl903141j

I believe this project is intended to be more of a 'design fiction' than a functioning photosynthetic material (RCA is well known for this type of work). Of course free organelles that aren't maintained by the cellular machinery will rapidly cease to function. They will maintain their green color but won't be able to perform membrane/macromolecule repair, gradient regulation, signaling, foreign body defense, etc.

This is still a useful project however as it may serve to catalyze future research into robust photosynthetic materials.

It's worth taking a look at the instructor, Kenneth Goldsmith's, bio[0]. He's one of the founders of UBUweb and MoMA's first poet laureate. He also had a recent interview with Stephen Colbert where they talk about his new book which consists of live television and radio transcripts of the moment announcers found out about major events in US history (JFK's assassination, 9/11, etc.) as a study on the language of improvisation.[1]

[0] http://en.wikipedia.org/wiki/Kenneth_Goldsmith

[1] http://thecolbertreport.cc.com/videos/5tqazj/kenneth-goldsmi...

Toby's a brilliant guy. Check out some of this other work here, some of which has been seen previously on HN. http://tobyschachman.com/

this was his favorite http://www.waymarking.com/cat/details.aspx?f=1&guid=5df351c0...

Just asked the author, will post if I find out.

I'll look into this. In the meantime, we did co-publish this essay with Rhizome.org. You can find their version here (same text).

http://rhizome.org/editorial/2014/may/20/stealth-infrastruct...

You can also find an interview with Julian Oliver here: http://vvvnt.com/media/julian-oliver

scaled it down, apologies.

fun video on how they found the images: https://vimeo.com/92583299

Can someone comment on whether it's feasible to port Atom to function in-browser? Seems like this + something like Codepen could potentially be an asset to frontend developers.

Time lag is a critical issue that needs to be accounted for. If we assume that innovation will mediate the worst effects of global warming then we neglect the possibility that forcing conditions created today may have consequences that manifest themselves over the next 20 or 50 years. Global warming is not like any problem that humanity has ever had to confront and it's dangerous to wave away the scale and complexity of the problem as something innovation will eventually rectify.

Here's the full architectural rendering from the book they mention – they seem to have adapted part of it for their splash page. You can definitely sink quite a bit of time looking at what's going on in each room.

http://www.deconcrete.org/wp-content/uploads/2010/03/Kowloon...

wow, fantastic work. If you provided embed codes for original compositions I'd definitely be using this quite a bit.

really well executed! I think the landing page could use some reorganization to feel really polished but this is amazing to play around with. Is there a way to lock a page from being edited at some point? Just so everyone knows, this is made in part by the developer of http://recursivedrawing.com & http://pixelshaders.com

reads like a syndicated article

This is a great point and I think many doctors are pushing for new ways to perform clinical trials but adaptive trials generally only change a single parameter during the course of a trial (dosage for example). And POC trials open up the number of patients that may be willing to participate by administering tests at local sites but the state of clinical trials still has a long way to go. Once it's firmly in drug companies' and insurance agencies' best interest to open things up then we may see more rapid change.

This technique is coming into prominence but genomic is still a very young science with the cost of sequencing only recently coming down enough to have it become regular practice. What we have now are essentially a shortlist of known mutations that are seen across many cancers, a huge list of closely associated mutations in the same pathway or impinging pathways that are sometimes seen in conjunction with other mutations, sometimes not and then a ton of noise from which researchers are trying to pick out possible correlation. The vast majority of mutations are not cancer causing, so picking out the ones that are is difficult. That being said, frequently broad characterization can be done. This person has an effected PI3Kinase, or MAP pathway. We only have drugs for a few of the major mutations so once the cancer mutates to avoid drugging, patients are often out of luck.

To answer your second question, cancer is generally accepted as a genetic disease ie mutations, copy number alterations, insertion and deletion of genetic information, however, recent research has shown that epigenetic processes (that is what your cells are doing with your genes such as alternative splicing or DNA methylation) are also an important factor and these can be effected by environmental factors such as diet, exercise, even mood.

I'm a bioinformatician at a translational cancer research institution & have some sense of the stumbling blocks and opportunities in this space.

First off, doing away with clinical trials as we perform them now would certainly speed up pairing drugs with patients but it's not going to happen unfortunately. Drug trials aren't designed to minimize search paths, they are designed to minimize risk.

With terminal diseases like many cancers the rules are bent a little but what's important to understand is that these are real people making the decisions ultimately. Sometimes the most information can be gained by withholding drug, and isolating another treatment's impact but if you are a patient with a terminal prognosis, or the doctor trying to treat that patient, are you going to choose not to take something that might help you?

This is a point of frustration for many in research fields because it means clinical data is hugely noisy. Patients are often cycled through different drugs quickly to find something that takes hold, while at the same time going in for as much chemo/radiation treatment as they can bare.

I'm not saying these approaches aren't relevant, they just won't happen as a grand reimagining of our drug approval system. What is starting to happen however, is reclassification of cancer 'type' based on genetic profiles meaning ovarian cancer may have certain genetic similarities to lung or pancreatic so instead of treating melanoma, you can treat a cancer with a disturbed MAP pathway.

All the same, I'm glad he's working on this problem because it's huge, and I look forward to seeing the point of view of the HN community.

edit: Though obvious to some, I should also mention this problem is complicated by the fact that genetic information is private and dissemination is highly restricted. Patients can release this info but it does often inhibit massive cross-patient research.

If you think about the people you know, the people you admire, how many of them are teachers? I would wager very few. The teaching profession (at least in the US) is not structured to attract quality candidates in the same way other professions do. The public / private divide exacerbates this problem. This requires money and legislation which makes the issue nearly intractable because efforts are most often put toward short-term gain rather than sustainable infrastructure.